Adult Dosing
Hemophilia A
- 0.3 mcg/kg slow IV infused over 15-30 mins, may repeat injection in 8-24 hrs
- Note: Give 30 min preoperatively for surgery; for patients with factor VIII levels > 5%
von Willebrand's disease Type I
- 0.3 mcg/kg slow IV infused over 15-30 mins, may repeat injection in 8-24 hrs
- Note: Give 30 min preoperatively for surgery; for patients with factor VIII levels > 5%
Neurohypophyseal diabetes insipidus
- 1-2 mcg/day SC/IV q12 hrs
- When switching from intranasal to parenteral, start with 1/10 dose
- Note: Lowest effective parenteral dose must be given. If tolerance develops during long term therapy, dose may be cautiously increased to achieve adequate therapeutic response
Pediatric Dosing
Hemophilia A
Child (> 3 mo)
- 0.3 mcg/kg slow IV infused over 15-30 mins, may repeat injection in 8-24 hrs
- Note: Give 30 min preoperatively for surgery; for patients with factor VIII levels > 5%
von Willebrand's disease Type I
Child (> 3 mo)
- 0.3 mcg/kg slow IV infused over 15-30 mins, may repeat injection in 8-24 hrs
- Note: Give 30 min preoperatively for surgery; for patients with factor VIII levels > 5%
Neurohypophyseal diabetes insipidus
Children (
12 yrs)
- 1-2 mcg/day SC/IV q12 hrs
- When switching from intranasal to parenteral, start with 1/10 dose
[Outline]
- Desmopressin [injectable] is not indicated for treatment of hemophilia A with factor VIII levels
5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies - Safety not established for use in infants <3 months of age for treatment of hemophilia A or von Willebrand’s disease, and in children <12 yrs of age with diabetes insipidus
- Rare, severe allergic reactions have been reported
- Reversible changes in blood pressure and increases in heart rate may occur with parenteral therapy
- Before starting therapy, check coagulation status in patients with hemophilia A and type I von Willebrand disease; monitor factor VIII coagulant activity, factor VIII antigen, ristocetin cofactor, activated PTT, and skin bleeding time
- Rare reports of hyponatremia from postmarketing experience; potent antidiuretic, may lead to water intoxication and/or hyponatremia. Fluid restriction recommended
- Use with caution in patients with habitual or psychogenic polydipsia; increased risk of hyponatremia due to consumption of excessive amounts of water
- Rare thrombotic events have been reported; use with caution in patients predisposed to thrombus formation
- Observe all patients for signs/symptoms of hyponatremia viz headache, nausea/vomiting, decreased serum sodium, weight gain, restlessness, fatigue, lethargy, disorientation, depressed reflexes, loss of appetite, irritability, muscle weakness, muscle spasms or cramps and abnormal mental status such as hallucinations, decreased consciousness and confusion
- An extreme decrease in plasma osmolality occurs rarely and may result in seizures and coma; Monitor urine volume and osmolality; plasma osmolality
Cautions: Use cautiously in
- Renal impairment (refer dosage adjustment section)
- Known or suspected CAD
- Hypertension
- Thrombosis risk
- Fluid and electrolyte imbalance
- Patients at risk for water intoxication with hyponatremia
- CHF
- Cystic fibrosis
- Geriatric population
- Pediatric population
Pregnancy Category:B
Breastfeeding: Safety unknown; minimally excreted in breast milk and poorly absorbed orally by the infant. Appears acceptable to use during breastfeeding. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 20 August 2010).
Pricing data from www.DrugStore.com in U.S.A.
- DDAVP 4 MCG/ML SOLN [Ampule] (SANOFI-AVENTIS U.S.)
1 ml = $59.3
3 ml = $151.7 - DDAVP 4 MCG/ML SOLN [Vial] (SANOFI-AVENTIS U.S.)
10 ml = $473.06
30 ml = $1418.04
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
